| Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s key product candidate, DSG3-CAART, is being evaluated for the treatment of mucosal pemphigus vulgaris (mPV), a subtype of PV that affects mucosal surfaces. Co.'s key preclinical product candidate, MuSK-CAART, is designed to treat a subset of patients with myasthenia gravis. Co. is also developing other product candidates in discovery-stage or preclinical development for the treatment of mucocutaneous PV, and Hemophilia A with Factor VIII, or FVIII, alloantibodies in addition to three undisclosed targets. We show 9 historical shares outstanding datapoints in our CABA shares outstanding history coverage, used to compute CABA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CABA market cap history over the course of time is important for investors
interested in comparing CABA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CABA versus a peer is one thing; comparing
CABA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CABA can fluctuate over the course of history.
With this page we aim to empower investors researching CABA by allowing them to research the CABA market cap history.